Immupharma Plc Stock Price To Earnings To Growth
| IMM Stock | 1.20 0.08 6.25% |
ImmuPharma PLC fundamentals help investors to digest information that contributes to ImmuPharma PLC's financial success or failures. It also enables traders to predict the movement of ImmuPharma Stock. The fundamental analysis module provides a way to measure ImmuPharma PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmuPharma PLC stock.
ImmuPharma | Price To Earnings To Growth |
ImmuPharma PLC Company Price To Earnings To Growth Analysis
ImmuPharma PLC's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, ImmuPharma PLC has a Price To Earnings To Growth of 0.0 times. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United Kingdom stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
ImmuPharma Fundamentals
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | 36.15 % | ||||
| Current Valuation | 4.77 M | ||||
| Shares Outstanding | 416.44 M | ||||
| Shares Owned By Insiders | 48.33 % | ||||
| Shares Owned By Institutions | 14.35 % | ||||
| Price To Book | 1.85 X | ||||
| Price To Sales | 60.75 X | ||||
| Gross Profit | 118.35 K | ||||
| EBITDA | (3.03 M) | ||||
| Net Income | (2.92 M) | ||||
| Total Debt | 1.67 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (1.36 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.58 | ||||
| Market Capitalization | 5.33 M | ||||
| Total Asset | 2.72 M | ||||
| Retained Earnings | (64.08 M) | ||||
| Working Capital | (321.92 K) | ||||
| Net Asset | 2.72 M |
About ImmuPharma PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmuPharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuPharma PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuPharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.